These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

261 related articles for article (PubMed ID: 27650765)

  • 1. Using serum urate as a validated surrogate end point for flares in patients with gout: protocol for a systematic review and meta-regression analysis.
    Morillon MB; Stamp L; Taylor W; Fransen J; Dalbeth N; Singh JA; Christensen R; Lassere M
    BMJ Open; 2016 Sep; 6(9):e012026. PubMed ID: 27650765
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Serum urate as surrogate endpoint for flares in people with gout: A systematic review and meta-regression analysis.
    Stamp L; Morillon MB; Taylor WJ; Dalbeth N; Singh JA; Lassere M; Christensen R
    Semin Arthritis Rheum; 2018 Oct; 48(2):293-301. PubMed ID: 29566967
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Variability in the Reporting of Serum Urate and Flares in Gout Clinical Trials: Need for Minimum Reporting Requirements.
    Stamp LK; Morillon MB; Taylor WJ; Dalbeth N; Singh JA; Lassere M; Christensen R
    J Rheumatol; 2018 Mar; 45(3):419-424. PubMed ID: 29247147
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Serum urate as a soluble biomarker in chronic gout-evidence that serum urate fulfills the OMERACT validation criteria for soluble biomarkers.
    Stamp LK; Zhu X; Dalbeth N; Jordan S; Edwards NL; Taylor W
    Semin Arthritis Rheum; 2011 Jun; 40(6):483-500. PubMed ID: 21056459
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Serum urate in chronic gout--will it be the first validated soluble biomarker in rheumatology?
    Stamp LK; Khanna PP; Dalbeth N; Boers M; Maksymowych WP; Schumacher HR; Becker MA; MacDonald PA; Edwards NL; Singh JA; Simon LS; McQueen FM; Neogi T; Gaffo AL; Strand V; Taylor WJ
    J Rheumatol; 2011 Jul; 38(7):1462-6. PubMed ID: 21724717
    [TBL] [Abstract][Full Text] [Related]  

  • 6. What Is the Evidence for Treat-to-Target Serum Urate in Gout?
    Bursill D; Dalbeth N
    Curr Rheumatol Rep; 2018 Mar; 20(3):11. PubMed ID: 29516287
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic factors associated with early gout flare recurrence in patients initiating urate-lowering therapy during an acute gout flare.
    Janssen CA; Oude Voshaar MAH; Ten Klooster PM; Vonkeman HE; van de Laar MAFJ
    Clin Rheumatol; 2019 Aug; 38(8):2233-2239. PubMed ID: 31030363
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effectiveness of an electronic patient-centred self-management tool for gout sufferers: a cluster randomised controlled trial protocol.
    Day RO; Frensham LJ; Nguyen AD; Baysari MT; Aung E; Lau AYS; Zwar N; Reath J; Laba T; Li L; McLachlan A; Runciman WB; Buchbinder R; Clay-Williams R; Coiera E; Braithwaite J; McNeil HP; Hunter DJ; Pile KD; Portek I; WIlliams KM; Westbrook JI
    BMJ Open; 2017 Oct; 7(10):e017281. PubMed ID: 29042386
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Outcome reporting in randomized trials in gout: A systematic scoping review from the OMERACT gout working group assessing the uptake of the core outcome set.
    Morillon MB; Nørup A; Singh JA; Dalbeth N; Taylor WJ; Kennedy MA; Pedersen BM; Grainger R; Tugwell P; Perez-Ruiz F; Diaz-Torne C; Edwards NL; Shea B; Ellingsen TJ; Christensen R; Stamp LK;
    Semin Arthritis Rheum; 2023 Jun; 60():152191. PubMed ID: 36963128
    [TBL] [Abstract][Full Text] [Related]  

  • 10. How flare prevention outcomes are reported in gout studies: A systematic review and content analysis of randomized controlled trials.
    Stewart S; Tallon A; Taylor WJ; Gaffo A; Dalbeth N
    Semin Arthritis Rheum; 2020 Apr; 50(2):303-313. PubMed ID: 31796212
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Serum urate as a proposed surrogate outcome measure in gout trials: From the OMERACT working group.
    Morillon MB; Christensen R; Singh JA; Dalbeth N; Saag K; Taylor WJ; Neogi T; Kennedy MA; Pedersen BM; McCarthy GM; Shea B; Diaz-Torne C; Tedeschi SK; Grainger R; Abhishek A; Gaffo A; Nielsen SM; Noerup A; Simon LS; Lassere M; Tugwell P; Stamp LK; Gout Working Group FTO
    Semin Arthritis Rheum; 2021 Dec; 51(6):1378-1385. PubMed ID: 34839932
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Patient and clinical characteristics associated with gout flares in an integrated healthcare system.
    Rashid N; Levy GD; Wu YL; Zheng C; Koblick R; Cheetham TC
    Rheumatol Int; 2015 Nov; 35(11):1799-807. PubMed ID: 25991397
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Urate-lowering therapy for the management of gout: a summary of 2 Cochrane reviews.
    Kydd AS; Seth R; Buchbinder R; Falzon L; Edwards CJ; van der Heijde DM; Bombardier C
    J Rheumatol Suppl; 2014 Sep; 92():33-41. PubMed ID: 25180126
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Association between serum urate and flares in people with gout and evidence for surrogate status: a secondary analysis of two randomised controlled trials.
    Stamp LK; Frampton C; Morillon MB; Taylor WJ; Dalbeth N; Singh JA; Doherty M; Zhang W; Richardson H; Sarmanova A; Christensen R
    Lancet Rheumatol; 2022 Jan; 4(1):e53-e60. PubMed ID: 38288731
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of a urate lowering regimen in primary gout.
    Bailén R; González Senac NM; López MM; Llena ML; Migoya M; Rodríguez MT; de Miguel E; Torres RJ; Puig JG
    Nucleosides Nucleotides Nucleic Acids; 2014; 33(4-6):174-80. PubMed ID: 24940666
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Serum Uric Acid and the Risk of Incident and Recurrent Gout: A Systematic Review.
    Shiozawa A; Szabo SM; Bolzani A; Cheung A; Choi HK
    J Rheumatol; 2017 Mar; 44(3):388-396. PubMed ID: 28148699
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and cost-effectiveness of nurse-led care involving education and engagement of patients and a treat-to-target urate-lowering strategy versus usual care for gout: a randomised controlled trial.
    Doherty M; Jenkins W; Richardson H; Sarmanova A; Abhishek A; Ashton D; Barclay C; Doherty S; Duley L; Hatton R; Rees F; Stevenson M; Zhang W
    Lancet; 2018 Oct; 392(10156):1403-1412. PubMed ID: 30343856
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Quality of care in gout: a clinical audit on treating to the target with urate lowering therapy in real-world gout patients.
    Janssen CA; Jansen TLTA; Oude Voshaar MAH; Vonkeman HE; van de Laar MAFJ
    Rheumatol Int; 2017 Sep; 37(9):1435-1440. PubMed ID: 28748426
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Achieving serum urate targets in gout: an audit in a gout-oriented rheumatology practice.
    Corbett EJM; Pentony P; McGill NW
    Int J Rheum Dis; 2017 Jul; 20(7):894-897. PubMed ID: 28205336
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 14.